<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02224040</url>
  </required_header>
  <id_info>
    <org_study_id>64/12</org_study_id>
    <nct_id>NCT02224040</nct_id>
  </id_info>
  <brief_title>Typhoid Fever: Combined vs. Single Antibiotic Therapy</brief_title>
  <official_title>Typhoid Fever: Combined vs. Single Antibiotic Therapy. A Prospective Randomized Controlled Study in Nepal.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study goal is to examine the effect of Cephalosporins, Azithromycin and the&#xD;
      combination of both on typhoid fever therapy in endemic population.&#xD;
&#xD;
      The investigator's hypothesize that the combination of azithromycin and ceftriaxone may prove&#xD;
      superior to each drug, ceftriaxone or azithromycin, alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Typhoid Fever is a highly prevalent infection in the Indian subcontinent. Due to multidrug&#xD;
      resistant strains in these areas, third generation cephalosporins, such as ceftriaxone, are&#xD;
      the treatment of choice. However, the latter regimen exhibits a slow response with mean time&#xD;
      of 5 to 7 days or even longer to defervescence, which could be attributed to poor penetration&#xD;
      capability of the drug into cells, and thus difficulty to eradicate the bacteria from the&#xD;
      intracellular niche.&#xD;
&#xD;
      Attempts have been made to overcome this setback by introducing alternative antibiotic&#xD;
      regimens, such as azithromycin. However studies comparing between azithromycin and a&#xD;
      third-generation cephalosporin for the treatment of typhoid fever in adult population in the&#xD;
      Indian subcontinent are lacking.&#xD;
&#xD;
      Over the last few years our approach towards non-immunized travelers, who acquired typhoid&#xD;
      fever in the Indian subcontinent, was to administer a combination therapy of intravenous&#xD;
      ceftriaxone with oral azithromycin. The rationale of this dual regimen was its&#xD;
      pharmacokinetic profile, which suggests a complimentary action of the two agents -&#xD;
      ceftriaxone on the extracellular compartment and azithromycin on the intracellular&#xD;
      compartment. Moreover, in our clinical experience, preliminary published data has proven&#xD;
      combination therapy significantly superior to ceftriaxone alone albeit in a small group of&#xD;
      travelers.&#xD;
&#xD;
      In the current study the investigators intend to compare the efficacy of ceftriaxone vs.&#xD;
      azithromycin and vs. combined therapy of both agents for the treatment of uncomplicated&#xD;
      typhoid fever in terms of time to defervescence.&#xD;
&#xD;
      4 different treatment strategies will be examined (as mentioned in the arm section). All&#xD;
      participants will be checked for vital signs, will undergo physical examination, ECG,&#xD;
      laboratory testing, blood, urine and stool culture and tests for susceptibility to&#xD;
      antibiotics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fever clearance time</measure>
    <time_frame>One month</time_frame>
    <description>Time to fever clearance will be measured and will be defined as an oral temperature that is below 37.50 C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>One month</time_frame>
    <description>Secondary endpoints will be treatment failure (defined as the need to switch antibiotic treatment according to physician's decision such as high grade fever after 5 days of treatment, appearance of typhoid complications under the treatment), clearance of bacteremia, development of typhoid-related complications, late relapse, fecal carriage and adverse drug reactions.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Typhoid Fever</condition>
  <arm_group>
    <arm_group_label>Ceftriaxone I.V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants in this arm will receive the following drug and dosage: adult: Ceftriaxone intravenous 2 gr once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day (maximum dose 2.5 g/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftriaxone I.V+Azithromycin P.O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants in this arm will receive the following drugs and dosages: adult: 2 g intravenous ceftriaxone and 500 mg oral azithromycin once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day and oral 20 mg/kg azithromycin suspension once a day. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin P.O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants in this arm will receive the following drug and dosage: adult: azithromycin oral 500 mg once a day. Pediatric: oral 20 mg/kg azithromycin suspension once a day (maximum dose 1000 mg/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin P.O+Cefixime P.O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants in this arm will receive the following drugs and dosages: adult: 500 mg azithromycin and 400 mg cefixime. Pediatric: oral 20 mg/kg azithromycin suspension once a day and oral 10 mg/kg cefixime. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
    <arm_group_label>Ceftriaxone I.V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone and azithromycin</intervention_name>
    <arm_group_label>Ceftriaxone I.V+Azithromycin P.O</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin</intervention_name>
    <arm_group_label>Azithromycin P.O</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin and cefixime</intervention_name>
    <arm_group_label>Azithromycin P.O+Cefixime P.O</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Blood culture-proven typhoid fever (S. typhi or S. paratyphi)&#xD;
&#xD;
          -  Signed informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to ceftriaxone or macrolides&#xD;
&#xD;
          -  Major typhoid fever-associated complications&#xD;
&#xD;
          -  Inability to swallow oral medication&#xD;
&#xD;
          -  Underlying illness&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lactation&#xD;
&#xD;
          -  Treatment within the past 4 days with an antibiotic that may be effective against&#xD;
             typhoid fever&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eli Schwartz, MD, DTMH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eli Schwartz, MD, DTMH</last_name>
    <phone>+97235308456</phone>
    <email>Eli.schwartz@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dhulikhel hospital</name>
      <address>
        <city>Dhulikhel</city>
        <zip>11008</zip>
        <country>Nepal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudeep Shrestha, M.D</last_name>
      <email>itsactionpotential@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>August 21, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2014</study_first_posted>
  <last_update_submitted>August 26, 2014</last_update_submitted>
  <last_update_submitted_qc>August 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Prof. Eli Schwartz MD, DTMH</investigator_full_name>
    <investigator_title>Principal Investigator of the geographic clinical</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhoid Fever</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Cefixime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

